EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder

Arushika Aggarwal, Simon Erridge, Madhur Varadpande iD, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal und 6 weitere

Neuropsychopharmacology Reports · 2026

DOI: 10.1002/npr2.70146 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neuropsychopharmacology Reports, 2026. Verfasst von Arushika Aggarwal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Cannabis Research Group, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Registries, Medical Marijuana. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges. This study aims to evaluate the change in health‐related quality of life (HRQoL), anxiety, and sleep quality in autistic individuals prescribed cannabis‐based medicinal products (CBMPs).

Method

This observational case series analyzed data from the UK Medical Cannabis Registry on autistic adults treated with CBMPs. Demographic and clinical data were collected at baseline, with patient‐reported outcome measures assessed up to 18 months. Primary outcomes included changes in anxiety (GAD‐7), sleep quality (SQS), and HRQoL (EQ‐5D‐5L). Secondary outcomes included the incidence of adverse events. Statistical significance was indicated by p < 0.050.

Results

One‐hundred and thirty individuals met the inclusion criteria. GAD‐7 ( p < 0.001) and SQS ( p < 0.001) scores improved from baseline to 18 months. EQ‐5D‐5L index values showed improvement from baseline (0.43 ± 0.30) to 18 months (0.51 ± 0.32, p < 0.001), and PGIC scores increased from 1 month (5.43 ± 1.49) to 18 months (5.65 ± 1.32, p = 0.013). Twenty‐five participants (19.23%) reported a total of 232 (178.46%) adverse events, with most being mild ( n = 88; 67.69%) or moderate ( n = 99; 76.15%).

Conclusion

Treatment with CBMPs was associated with improvements in HRQoL, anxiety, and sleep outcomes in autistic patients over an 18‐month period. Given the absence of a control group, these findings represent associations rather than proven treatment effects. Further high‐quality randomized controlled trials are needed to confirm the long‐term efficacy and safety of CBMPs in ASD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderRegistriesMedical MarijuanaHumansFemaleMaleQuality of LifeAdultUnited KingdomAnxietySleep QualityYoung AdultAdolescentTreatment Outcome

Stichwörter der Autor:innen

anxietyautism spectrum disordercannabidiolcannabistetrahydrocannabinol

Substanzen

Medical Marijuana

Autor:innen und Institutionen

  • Medical Cannabis Research Group, Imperial College London, London, UK.
  • Curaleaf Clinic, London, UK.
  • St. George's Hospital NHS Trust, London, UK.
  • Department of Psychological Medicine, Kings College London, London, UK.
  • South London & Maudsley NHS Foundation Trust, London, UK.

ORCID-Profile: Madhur Varadpande, Mikael H Sodergren

Zitieren

APA

Aggarwal, A., Erridge, S., Varadpande, M., Clarke, E., McLachlan, K., Coomber, R., Asghar, M., Bhoskar, U., Crews, M., De Angelis, A., Imran, M., Kamal, F., Korb, L., Mwimba, G., Sachdeva-Mohan, S., Shaya, G., Rucker, J. J., & Sodergren, M. H. (2026). UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70146

Vancouver

Aggarwal A, Erridge S, Varadpande M, Clarke E, McLachlan K, Coomber R, et al. UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder. Neuropsychopharmacology Reports. 2026. doi:10.1002/npr2.70146

BibTeX
@article{Aggarwal2026,
  author = {Aggarwal, Arushika and Erridge, Simon and Varadpande, Madhur and Clarke, Evonne and McLachlan, Katy and Coomber, Ross and Asghar, Muhammed and Bhoskar, Urmila and Crews, Matthieu and De Angelis, Andrea and Imran, Muhammad and Kamal, Fariha and Korb, Laura and Mwimba, Gracia and Sachdeva-Mohan, Simmi and Shaya, Gabriel and Rucker, James J and Sodergren, Mikael H},
  title = {UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder},
  journal = {Neuropsychopharmacology Reports},
  year = {2026},
  doi = {10.1002/npr2.70146}
}
Kostenlos starten →